protocolSection identificationModule nctId: NCT06339567, orgStudyIdInfo id: 671_Hemo-PCOS, briefTitle: Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study, acronym: Hemo-PCOS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-08, primaryCompletionDateStruct date: 2026-02-07, completionDateStruct date: 2029-02-07, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Fondation Hôpital Saint-Joseph, class: OTHER, descriptionModule briefSummary: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of childbearing age. PCOS can be individualized into several phenotypes, taking into account in particular the presence of hyperandrogenism, insulin resistance and BMI. Hyperandrogenism and insulin resistance appear to be important factors in the development of cardiovascular cardiovascular disease. In addition, patients frequently use anti-androgenic and/or contraceptive treatments contraceptives, such as combined hormonal contraception (CHC), the use of which is associated with an increased cardiovascular and thrombo and venous thrombosis (VTE). A meta-analysis published in 2020 by Gariani et al.based on three large studies, estimated the risk of VTE in women with PCOS after adjustment for obesity and hormone therapy. This risk was significantly higher compared with women without PCOS (pooled OR 1.89, CI95% 1.60-2.24). No study has looked specifically investigated the risk of VTE according to different PCOS phenotypes. Such data would be very useful in clinical practice, as it would enable monitoring, contraceptive treatment and anti-androgenic anti-androgen treatment according to the PCOS phenotype, while limiting risks. Assessing the differences PCOS phenotypes is limited by the large sample size required. required. VTE is a rare event in women of childbearing age, and the number of PCOS phenotypes is high.PCOS phenotypes. Intermediate markers of VTE risk are used in these situations. These markers are thrombin generation tests (notably ETP) and their sensitivity to activated protein C (nAPCsr) and thrombomodulin (nTMsr), as well as sex-hormone binding globulin (SHBG)., conditionsModule conditions: Polycystic Ovary Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 320, type: ESTIMATED, armsInterventionsModule interventions name: Thrombotic profile, outcomesModule primaryOutcomes measure: biological procoagulant profile, secondaryOutcomes measure: Insuline resistance and weight, secondaryOutcomes measure: comparison of procoagulant profile depending on insulin resistance, secondaryOutcomes measure: comparison of procoagulant profile depending on hyperangrogenism, secondaryOutcomes measure: comparison of procoagulant profile depending on PCOS phenotype, secondaryOutcomes measure: comparison of procoagulant profile depending on AMH Rate, secondaryOutcomes measure: comparison of QoL score depending on PCOS phenotype, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Hôpital Paris Saint Joseph, status: RECRUITING, city: Paris, country: France, contacts name: Juliette COURTIADE MAHLER, role: CONTACT, email: jcourtiade@ghpsj.fr, contacts name: Hélène Beaussier, pharmaD, role: CONTACT, email: hbeaussier@ghpsj.fr, geoPoint lat: 48.85341, lon: 2.3488, hasResults: False